PepGen Inc. - Common Stock (PEPG)

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the pricing of an underwritten offering of 31,250,000 shares of its common stock at a price to the public of $3.20 per share. The aggregate gross proceeds to PepGen from this offering are expected to be $100 million, before deducting underwriting discounts and commissions and offering expenses payable by PepGen. The offering is expected to close on or about September 26, 2025, subject to customary closing conditions. In addition, PepGen has granted the underwriters a 30-day option to purchase up to 4,687,500 additional shares of common stock at the public offering price, less the underwriting discount.

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it has commenced an underwritten public offering of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. All of the shares and pre-funded warrants are being offered by PepGen. In addition, PepGen intends to grant the underwriters a 30-day option to purchase additional shares of its common stock. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company developing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, announced positive clinical data today from the 15 mg/kg dose cohort of its ongoing FREEDOM-DM1 Phase 1 single ascending dose (SAD) study in patients with myotonic dystrophy type 1 (DM1). These latest results demonstrated a mean splicing correction of 53.7% following a single 15 mg/kg dose of PGN-EDODM1, substantially higher than any previously reported splicing correction in DM1 patients.

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) and reminds investors of the August 11, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

NEW YORK - August 8, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in PepGen Inc. (NASDAQ: PEPG) of a class action securities lawsuit.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In PepGen (PEPG) To Contact Them Directly To Discuss Their Options

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK - August 7, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in PepGen Inc. (NASDAQ: PEPG) of a class action securities lawsuit.

PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today reported financial results and recent corporate highlights for the quarter ended June 30, 2025.

NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) --

NEW YORK - August 6, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in PepGen Inc. (NASDAQ: PEPG) of a class action securities lawsuit.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In PepGen (PEPG) To Contact Them Directly To Discuss Their Options

NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) and certain officers.   The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 25-cv-03221, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired PepGen securities between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In PepGen To Contact Him Directly To Discuss Their Options

NEW YORK - August 5, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in PepGen Inc. (NASDAQ: PEPG) of a class action securities lawsuit.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK - August 4, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in PepGen Inc. (NASDAQ: PEPG) of a class action securities lawsuit.

NEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.

Bragar Eagel & Squire, P.C. Litigation Attorneys Encourage Investors Who Suffered Losses In PepGen (PEPG) To Contact Them Directly To Discuss Their Options

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

NEW YORK - August 1, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in PepGen Inc. (NASDAQ: PEPG) of a class action securities lawsuit.

NEW YORK, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG) and certain officers.   The class action, filed in the United States District Court for the Eastern District of New York, and docketed under 25-cv-03221, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired PepGen securities between March 7, 2024 and March 3, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants’ violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.